Assertio Therapeutics Announces Third-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St muted as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 3% as Iran tempers hopes of Hormuz reopening
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
November 8, 2018 4:26 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.42, $0.16 better than the analyst estimate of $0.26. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $73.7 million.
Our third-quarter performance positions us well to achieve our neurology franchise net sales and... More
Assertio Therapeutics (ASRT) Tops Q3 EPS by 16c; Raises FY EPS Guidance
November 8, 2018 4:26 PM ESTAssertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.42, $0.16 better than the analyst estimate of $0.26. Revenue for the quarter came in at $77.5 million versus the consensus estimate of $73.7 million.
Our third-quarter performance positions us well to achieve our neurology franchise net sales and... More
